Monica Bertagnolli

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors
    Nancy L Cho
    Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Surg Res 173:320-6. 2012
  2. pmc Sentinel node staging of resectable colon cancer: results of a multicenter study
    Monica Bertagnolli
    Brigham and Women s Hospital, Boston, MA, USA
    Ann Surg 240:624-8; discussion 628-30. 2004
  3. ncbi request reprint Surgical prevention of cancer
    Monica M Bertagnolli
    Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Clin Oncol 23:324-32. 2005
  4. pmc Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803
    Monica M Bertagnolli
    Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Clin Oncol 29:3153-62. 2011
  5. pmc Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803
    Monica M Bertagnolli
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 27:1814-21. 2009
  6. pmc p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 15:2116-22. 2009
  7. pmc Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 2:310-21. 2009
  8. pmc Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 3:588-96. 2010
  9. ncbi request reprint Celecoxib for the prevention of sporadic colorectal adenomas
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, USA
    N Engl J Med 355:873-84. 2006
  10. ncbi request reprint Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet Oncol 8:439-43. 2007

Detail Information

Publications48

  1. doi request reprint Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors
    Nancy L Cho
    Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Surg Res 173:320-6. 2012
    ..Partial response to tyrosine kinase inhibitors (TKI) has previously been described. Here, we examined the role of the tyrosine kinases c-Src and c-Kit in driving desmoid tumorigenesis...
  2. pmc Sentinel node staging of resectable colon cancer: results of a multicenter study
    Monica Bertagnolli
    Brigham and Women s Hospital, Boston, MA, USA
    Ann Surg 240:624-8; discussion 628-30. 2004
    ..This study, conducted by 25 surgeons at 13 institutions, examined whether sentinel node (SN) sampling accurately predicted LN status for patients with resectable colon cancer...
  3. ncbi request reprint Surgical prevention of cancer
    Monica M Bertagnolli
    Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Clin Oncol 23:324-32. 2005
    ..This article briefly reviews the use of surgery to prevent some of the most common epithelial malignancies, as well as some of the genetic cancer syndromes for which surgery plays an important role in improving survival...
  4. pmc Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803
    Monica M Bertagnolli
    Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Clin Oncol 29:3153-62. 2011
    ..Colorectal cancer (CRC) develops as a result of a series of accumulated genomic changes that produce oncogene activation and tumor suppressor gene loss. These characteristics may classify CRC into subsets of distinct clinical behaviors...
  5. pmc Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803
    Monica M Bertagnolli
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 27:1814-21. 2009
    ..This prospective study investigated adjuvant chemotherapy containing FU and irinotecan in patients with MMR deficient (MMR-D) colon cancers...
  6. pmc p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 15:2116-22. 2009
    ..In a prospective study, we validated this relationship in patients enrolled on a trial of adjuvant chemotherapy for stage III colon cancer...
  7. pmc Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 2:310-21. 2009
    ....
  8. pmc Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 3:588-96. 2010
    ..For patients at high risk of colorectal cancer, statins do not protect against colorectal neoplasms and may even increase the risk of developing colorectal adenomas...
  9. ncbi request reprint Celecoxib for the prevention of sporadic colorectal adenomas
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, USA
    N Engl J Med 355:873-84. 2006
    ....
  10. ncbi request reprint Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet Oncol 8:439-43. 2007
    ....
  11. ncbi request reprint Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1071-80. 2005
    ..Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern...
  12. ncbi request reprint Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors
    Chandrajit P Raut
    Department of Surgery, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 24:2325-31. 2006
    ..To assess the role of surgery in multimodality management of GISTs, we studied postoperative outcomes in patients treated with targeted kinase inhibitors for advanced GIST...
  13. pmc Association of family history with cancer recurrence and survival among patients with stage III colon cancer
    Jennifer A Chan
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:2515-23. 2008
    ..However, the influence of family history on cancer recurrence and survival among patients with established disease remains uncertain...
  14. ncbi request reprint Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 114:1028-35. 2006
    ..Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal adenomas but have been associated with increased cardiovascular risk...
  15. doi request reprint Aberrant crypt foci in the adenoma prevention with celecoxib trial
    Nancy L Cho
    Department of Surgery, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 1:21-31. 2008
    ..Our overall results indicated that nondysplastic ACF were not accurate surrogate endpoint biomarkers of recurrent colorectal adenomas in the APC trial...
  16. ncbi request reprint Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor
    Adelaide M Carothers
    Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Res 66:6432-8. 2006
    ..Chronic uninterrupted celecoxib treatment, however, induces untoward effects that enhance early progression events in intestinal tumorigenesis and may contribute to treatment toxicity...
  17. pmc Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 117:2104-13. 2008
    ..Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events...
  18. pmc Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis
    Adelaide M Carothers
    Department of Surgery, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Res 70:4433-42. 2010
    ..Our findings argue that celecoxib resistance is an acquired adaptation to changes in the crypt microenvironment that is associated with chronic intestinal inflammation and impaired acute wound-healing responsiveness...
  19. doi request reprint Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma
    Chandrajit P Raut
    Department of Surgery, Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States
    Eur J Cancer 45:2818-24. 2009
    ..Neither has been validated in ULMS. We critically evaluated both systems to determine if either identified patient groups with distinct outcomes...
  20. ncbi request reprint Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility
    Adelaide M Carothers
    Department of Surgery, Carrie Hall, Room 116, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Exp Cell Res 312:387-400. 2006
    ..Thus, the positive regulation of E-cadherin adhesion provided by Apc+ in vivo allows proper negative regulation of Egfr, Src, Pyk2, and MAPK, as well as RhoA activities...
  21. pmc Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma
    Andrew T Chan
    Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Gastroenterology 136:2127-2136.e1. 2009
    ..We examined the influence of CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants on dose-related response or toxicity in a randomized trial of celecoxib...
  22. ncbi request reprint Current management of metastatic gastrointestinal stromal tumor: a case report
    Suzanne George
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Adv Hematol Oncol 1:63-4; discussion 65. 2003
  23. doi request reprint Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate
    Chandrajit P Raut
    Department of Surgery, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 17:407-15. 2010
    ..Impact of surgery in IM-resistant patients on second-line sunitinib (SU) is unknown...
  24. ncbi request reprint Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer
    Matthew H Kulke
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Thorac Cardiovasc Surg 127:1579-86. 2004
    ....
  25. doi request reprint A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions
    Lori J Wirth
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 1:339-48. 2008
    ..Treatment with celecoxib in subjects with OPLs favorably modulates the primary mediator of cyclooxygenase-2 activity, PGE(2), after 12 weeks...
  26. ncbi request reprint Adenomatous polyposis coli truncation alters cytoskeletal structure and microtubule stability in early intestinal tumorigenesis
    Sara A Hughes
    Department of Surgery, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Gastrointest Surg 6:868-74; discussion 875. 2002
    ..These changes are consistent with the defects in enterocyte migration and junctional complex formation observed in the Min/+ model of early APC-associated colorectal tumorigenesis...
  27. pmc Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis
    Jennifer S Davids
    Department of Surgery, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 3:348-58. 2010
    ..We conclude that chronic COX-2 inhibition alters TGFbeta signaling in the intestinal mucosa, producing conditions consistent with chronic inflammation...
  28. pmc KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:7322-9. 2009
    ....
  29. ncbi request reprint Leiomyosarcoma of the inferior vena cava: survival after aggressive management
    Hiromichi Ito
    Department of Surgery, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 14:3534-41. 2007
    ..Leiomyosarcoma (LMS) of the inferior vena cava (IVC) is exceedingly rare. The role of adjuvant therapy remains undefined. This study evaluated outcomes after aggressive management...
  30. ncbi request reprint Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001
    Mark Redston
    Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Oncol 24:878-83. 2006
    ..To determine whether sentinel lymph node (LN) sampling (SLNS) could reduce the number of nodes required to characterize micrometastatic disease (MMD) in patients with potentially curable colon cancer...
  31. ncbi request reprint Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer
    Sara H Javid
    Department of Surgery, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Carcinogenesis 26:587-95. 2005
    ..In conclusion, both coumestrol and E(2) prevent intestinal tumorigenesis and ameliorate enterocyte migration and intercellular adhesion in the Apc(Min/+) mouse model of CRC...
  32. ncbi request reprint Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice
    Nancy L Cho
    Departments of Surgery and Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 67:2366-72. 2007
    ..Our results indicate that ERalpha and ERbeta are inhibitory modifiers of Apc-dependent colon tumorigenesis. As a result, loss of E(2) and ER signaling in postmenopausal women may contribute to colorectal cancer development...
  33. ncbi request reprint Cox-2 and cancer chemoprevention: picking up the pieces
    Monica M Bertagnolli
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Recent Results Cancer Res 174:73-8. 2007
    ..This article will discuss the biologic rationale for using selective Cox-2 inhibitors in cancer chemoprevention, and outline new avenues of research necessary to allow their successful use in patients at risk for colorectal cancer...
  34. doi request reprint BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells
    Mala Mani
    Department of Medical Oncology and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 69:7577-86. 2009
    ..The pleiotropic roles of BCL9 reported in this study underscore its value as a drug target for therapeutic intervention in several malignancies associated with aberrant Wnt signaling...
  35. doi request reprint Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells
    Chi Iou Lin
    Department of Surgery, Brigham and Women s Hospital, 20 Shattuck St, Thorn 1503, Boston, MA 02115, USA
    Biochem Biophys Res Commun 379:626-31. 2009
    ..These observations support further evaluation of Gal-3 as a potential therapeutic target in patients with aggressive PTC...
  36. doi request reprint Multimodality treatment of mesenteric desmoid tumours
    Monica M Bertagnolli
    Department of Surgery, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Eur J Cancer 44:2404-10. 2008
    ..When desmoids arise in the intestinal mesentery, surgical resection is seldom possible without life-altering loss of intestinal function...
  37. ncbi request reprint Colorectal cancer prevention studies: the importance of defining disease risk
    Monica M Bertagnolli
    Ann Surg Oncol 10:829-30. 2003
  38. ncbi request reprint Characterization of sporadic colon cancer by patterns of genomic instability
    Ajay Goel
    Department of Medicine and Cancer Center, University of California at San Diego, La Jolla, California, USA
    Cancer Res 63:1608-14. 2003
    ..Our data suggest that molecular mechanisms of genomic instability are not necessarily independent and may not be fully defined by either the MSI or CIN pathways...
  39. ncbi request reprint Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, US Oncology, Collins 5, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Cancer Res 8:314-46. 2002
    ..The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer...
  40. ncbi request reprint Carnosol inhibits beta-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse
    Amy E Moran
    Department of Surgery, New York Presbyterian Hospital and Weill Medical College of Cornell University, New York, NY, USA
    Cancer Res 65:1097-104. 2005
    ..Moreover, these data suggest that carnosol prevents Apc-associated intestinal tumorigenesis, potentially via its ability to enhance E-cadherin-mediated adhesion and suppress beta-catenin tyrosine phosphorylation...
  41. ncbi request reprint The potential of non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention
    Monica M Bertagnolli
    J Surg Oncol 84:113-9. 2003
  42. ncbi request reprint Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice
    Amy E Moran
    Department of Surgery, Weill College of Medicine of Cornell University, and Strang Cancer Prevention Center, New York, New York 10021, USA
    J Biol Chem 279:43261-72. 2004
    ....
  43. ncbi request reprint Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer
    Christian N Arnold
    Department of Medicine and Cancer Center, University of California, San Diego, La Jolla, California, USA
    Cancer Biol Ther 3:73-8. 2004
    ..We aimed to investigate the association between MSI status, hMLH1 protein expression and methylation status of the hMLH1 promoter, and to determine the usefulness of each method in defining the MSI phenotype in sporadic CRCs...
  44. ncbi request reprint Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers
    Ajay Goel
    Department of Medicine and Comprehensive Cancer Center, University of California San Diego, La Jolla, California, USA
    Cancer Res 64:3014-21. 2004
    ....
  45. ncbi request reprint Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers
    Ajay Goel
    Department of Medicine and Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA
    Int J Cancer 112:754-9. 2004
    ..The significant association of RUNX3 promoter hypermethylation with MSI-H colon cancers suggests that RUNX3 is a novel target of methylation, along with the hMLH1 gene, in the evolution of MSI-H colorectal cancers...
  46. ncbi request reprint APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q
    Christian N Arnold
    Department of Medicine and Comprehensive Cancer Center, University of California San Diego, La Jolla, California, USA
    Cancer Biol Ther 3:960-4. 2004
    ..Recently, it has been demonstrated that epigenetic modification of the APC promoter influences APC silencing. Here we examined the influence of APC methylation on APC expression in tumors with and without LOH at the APC locus...
  47. ncbi request reprint Radioimmunotherapy for colorectal cancer
    Monica M Bertagnolli
    Clin Cancer Res 11:4637-8. 2005
  48. ncbi request reprint The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer
    Ajay Goel
    Division of Gastroenterology, Department of Internal Medicine and Baylor Charles A Sammons Cancer Center, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Gastroenterology 132:127-38. 2007
    ..The majority of MSS CRCs demonstrate chromosomal instability (CIN) with frequent loss of heterozygosity (LOH) at key tumor suppressor genes. We hypothesized that the majority of sporadic CRCs without CIN would be associated with CIMP...